Microbially Guided Discovery and Biosynthesis of Biologically Active Natural Products.
Ankur SarkarEdward Y KimTaehwan JangAkarawin HongdusitHyungjun KimJeong-Mo ChoiJerome M FoxPublished in: ACS synthetic biology (2021)
The design of small molecules that inhibit disease-relevant proteins represents a longstanding challenge of medicinal chemistry. Here, we describe an approach for encoding this challenge-the inhibition of a human drug target-into a microbial host and using it to guide the discovery and biosynthesis of targeted, biologically active natural products. This approach identified two previously unknown terpenoid inhibitors of protein tyrosine phosphatase 1B (PTP1B), an elusive therapeutic target for the treatment of diabetes and cancer. Both inhibitors appear to target an allosteric site, which confers selectivity, and can inhibit PTP1B in living cells. A screen of 24 uncharacterized terpene synthases from a pool of 4464 genes uncovered additional hits, demonstrating a scalable discovery approach, and the incorporation of different PTPs into the microbial host yielded alternative PTP-specific detection systems. Findings illustrate the potential for using microbes to discover and build natural products that exhibit precisely defined biochemical activities yet possess unanticipated structures and/or binding sites.
Keyphrases
- small molecule
- living cells
- high throughput
- protein protein
- fluorescent probe
- microbial community
- endothelial cells
- type diabetes
- papillary thyroid
- cardiovascular disease
- single molecule
- squamous cell carcinoma
- emergency department
- high resolution
- genome wide
- loop mediated isothermal amplification
- human health
- adipose tissue
- cancer therapy
- drug discovery
- single cell
- amino acid
- combination therapy
- risk assessment
- mass spectrometry
- climate change
- lymph node metastasis
- drug induced
- quantum dots
- structural basis